SCHEMBL5357019

SCHEMBL5357019

O=C1c2cccc(N3CCNCC3)c2Oc2ccccc2N1Cc1cccc(Cl)c1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.64
MAPT P10636 3/20 0.47
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
CASP6 P55212 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH3A1 P30838 1/20 0.45
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
TP53 P04637 3/20 0.43
POLB P06746 1/20 0.43
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5372213 0.93 HTR6 (0.68) HTR6MAPTLMNASMN1; SMN2MEN1
SCHEMBL5364893 0.92 HTR6 (0.65) HTR6MAPTALDH3A1
SCHEMBL5361668 0.90 HTR6 (0.66) HTR6MAPTLMNASMN1; SMN2MEN1
SCHEMBL5364738 0.90 HTR6 (0.79) HTR6MAPTLMNASMN1; SMN2MEN1
SCHEMBL5364868 0.90 HTR6 (0.69) HTR6MAPTLMNASMN1; SMN2MEN1
SCHEMBL5366734 0.88 HTR6 (0.64) HTR6SMN1; SMN2KMT2A
SCHEMBL5366505 0.88 HTR6 (0.74) HTR6MAPTLMNAMEN1KMT2A
SCHEMBL5361817 0.88 HTR6 (0.64) HTR6MAPTLMNASMN1; SMN2MEN1
SCHEMBL5360234 0.87 HTR6 (0.83) HTR6MAPTLMNASMN1; SMN2
SCHEMBL5356074 0.87 HTR6 (0.59) HTR6MAPTLMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US claimed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US claimed
WO-2006061126-A2 DIBENZOXAZEPINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-15 WO claimed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US disclosed
WO-2006061126-A2 DIBENZOXAZEPINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof HTR6, BDKRB1, HTR7 HTR6 1/4885MAPT 4738/4885LMNA 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.